Abstract 514P
Background
Glioblastoma (GBM) is the most aggressive brain tumor in adults and is characterized by an immunosuppressive microenvironment. Different factors shaping its tumor microenvironment (TME) regulate tumor initiation, progression, and treatment response. The aim of this study was to characterize the TME and the expression of immunomodulatory targets in patients (pts) with GBM.
Methods
Immunohistochemistry for CD3, CD4, CD8, programed death ligand 1 (PD-L1) and programed death 1 (PD1) was performed on surgical tumor specimens from pts diagnosed with GBM, according to the CNS WHO 2021 criteria. A descriptive statistic was applied to the data set. OS and PFS were estimated through the Kaplan-Meier method and analyzed by the means of a log-rang test.
Results
We included 30 pts, with median age of 59.8 years [range 40.2-69.1 years]. All pts were treated with surgery followed by temozolomide concurrent with and adjuvant to radiotherapy. MGMT was methylated in 46.7% of pts and unmethylated in 53.3% of pts. Overall CD4+ lymphocytes, both intratumoral and perivascular, were significantly more represented than CD8+ lymphocytes in the GBM TME (p= 0.01). A lower density of CD4+ lymphocytes (<10%) was found to be a favorable prognostic factor for GBM outcome (p= 0.02). Pts with MGMT methylated and unmethylated tumors exhibited a distinct TME composition, with a significant higher number of perivascular CD8+ lymphocytes (p= 0.002), intratumoral CD8+ lymphocytes (p= 0.0024) and perivascular CD4+ lymphocytes (p=0.014) in MGMT unmethylated compared to MGMT methylated tumors. PD-L1 expression in GBM cell surface was 13.3% (n=4) and PD1 was expressed in 30% (N=9) of the GBM-infiltrating T cells, with predominantly perivascular distribution.
Conclusions
CD4+ lymphocytes lower density (<10%) correlates with improved survival. Given the small numbers of our cohort, the prognostic value of CD4+ lymphocytes density needs to be validated in large-scale studies. MGMT methylated and unmethylated tumors exhibit different immune profiles, reflecting the different biology of these tumors. The expression of PD-L1 and PD1 in GBM patients is confined to a small subpopulation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
67P - The effect of non-viral gene-immune therapy via OX40L or 4-1BBL on murine subcutaneous CT26 colon cancer model
Presenter: Olga Rakitina
Session: Poster session 09
68P - Dendritic polylysine with paclitaxel and triptolide codelivery for enhanced NSCLC ferroptosis through the accumulation of ROS
Presenter: Huae Xu
Session: Poster session 09
69P - Novel monoclonal antibodies can distinguish Cripto-1 from Cripto-3 proteins: Clinical implications and potential new biomarkers
Presenter: Josune Garcia-Sanmartin
Session: Poster session 09
70P - The human intratumor mycobiome is significantly influenced by an individual's race
Presenter: Dan Coster
Session: Poster session 09
71P - Preclinical characterization of ARX305: A next-generation anti-CD70 antibody drug conjugate for the treatment of CD70-expressing cancers
Presenter: Lillian Skidmore
Session: Poster session 09
72P - Impact of extended panel of genes for germline cancer testing
Presenter: Shaheenah Dawood
Session: Poster session 09
73P - Preclinical and clinical presentation of the nerve-driven tumor spread
Presenter: Dawid Sigorski
Session: Poster session 09
74P - Characterization of ERBB2 variation and their association with immune response in solid tumours
Presenter: Dong Wang
Session: Poster session 09
75P - Double-stranded RNA transfection induced anti-tumour effect mediated by dual RIG-I and TLR-3 immune pathways
Presenter: Jiayu Tai
Session: Poster session 09
76P - Improvement of whole-cell cancer vaccine anti-tumor effect by different injection methods
Presenter: Chin yang Chang
Session: Poster session 09